The Effects of Inhaled Nitric Oxide on Postoperative Pulmonary Hypertension in Infants and Children Undergoing Surgical Repair of Congenital Heart Disease

Russell, Isobel A.; Zwass, Maurice S.; Fineman, Jeffrey R.; Balea, Michel; Rouine‐Rapp, Kathryn; Brook, Michael M.; Hanley, Frank L.; Silverman, Norman H.; Cahalan, Michael K.

doi:10.1213/00000539-199807000-00011

Cited by 83 publications

(19 citation statements)

References 10 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…32 No difference between groups was found when comparing mean systemic arterial pressure, heart rate, and arterial pressure following initiation of INO. 32 The authors concluded that INO selectively decreases mean pulmonary artery pressure in children with pulmonary hypertension following cardiopulmonary bypass surgery. 32 Limitations of this study have created some questions regarding the author's findings.…”

Section: Congenital and Acquired Cardiac Disease/post-cardiac Surgerymentioning

confidence: 93%

“…32 All subjects with pulmonary hypertension responded to INO with an average reduction of 19% in mean pulmonary artery pressure at 20 min. 32 No difference between groups was found when comparing mean systemic arterial pressure, heart rate, and arterial pressure following initiation of INO. 32 The authors concluded that INO selectively decreases mean pulmonary artery pressure in children with pulmonary hypertension following cardiopulmonary bypass surgery.…”

Section: Congenital and Acquired Cardiac Disease/post-cardiac Surgerymentioning

confidence: 98%

“…29,30 Early small studies evaluated the effect of INO for the treatment of pulmonary hypertension for surgical repair of congenital heart disease ( Table 2). Russell et al 32 used a randomized controlled double-blind study to compare 40 children undergoing cardiopulmonary bypass for repair of congenital cardiac lesions. Pulmonary hypertension was defined as a mean pulmonary artery pressure Ͼ 50% of the mean systemic arterial pressure.…”

Section: Congenital and Acquired Cardiac Disease/post-cardiac Surgerymentioning

confidence: 99%

“…Pulmonary hypertension was defined as a mean pulmonary artery pressure Ͼ 50% of the mean systemic arterial pressure. 32 Thirteen subjects (36%) were separated from cardiopulmonary bypass with pulmonary hypertension. 32 All subjects with pulmonary hypertension responded to INO with an average reduction of 19% in mean pulmonary artery pressure at 20 min.…”

Section: Congenital and Acquired Cardiac Disease/post-cardiac Surgerymentioning

confidence: 99%

“…32 Thirteen subjects (36%) were separated from cardiopulmonary bypass with pulmonary hypertension. 32 All subjects with pulmonary hypertension responded to INO with an average reduction of 19% in mean pulmonary artery pressure at 20 min. 32 No difference between groups was found when comparing mean systemic arterial pressure, heart rate, and arterial pressure following initiation of INO.…”

Section: Congenital and Acquired Cardiac Disease/post-cardiac Surgerymentioning

confidence: 99%

See 4 more Smart Citations

Inhaled Pulmonary Vasodilators: Are There Indications Within the Pediatric ICU?

Kuch

Saville²,

Sanchez‐de‐Toledo

et al. 2017

Respir Care

View full text Add to dashboard Cite

Inhaled nitric oxide (INO) is only FDA-cleared for neonates (> 34 weeks gestation) with hypoxic respiratory failure-associated pulmonary hypertension. Off-label use of INO is common in the pediatric population despite a lack of evidence regarding survival benefit, questioning whether the therapy should be considered outside the neonatal period. A lack of definitive evidence combined with increasing health-care costs has led to the use of less costly inhaled prostacyclin as an alternative to INO, presenting unique patient safety concerns. We evaluate the current evidence and patient safety considerations regarding inhaled pulmonary vasodilators in the pediatric population.

show abstract

Section: Congenital and Acquired Cardiac Disease/post-cardiac Surgerymentioning

confidence: 93%

Section: Congenital and Acquired Cardiac Disease/post-cardiac Surgerymentioning

confidence: 98%

Section: Congenital and Acquired Cardiac Disease/post-cardiac Surgerymentioning

confidence: 99%

Section: Congenital and Acquired Cardiac Disease/post-cardiac Surgerymentioning

confidence: 99%

Section: Congenital and Acquired Cardiac Disease/post-cardiac Surgerymentioning

confidence: 99%

See 3 more Smart Citations

Inhaled Pulmonary Vasodilators: Are There Indications Within the Pediatric ICU?

Kuch

Saville²,

Sanchez‐de‐Toledo

et al. 2017

Respir Care

View full text Add to dashboard Cite

show abstract

Inhaled nitric oxide for the postoperative management of pulmonary hypertension in infants and children with congenital heart disease

Bizzarro¹,

Gross²

2005

Cochrane Database of Systematic Reviews

View full text Add to dashboard Cite

Inhaled nitric oxide for the postoperative management of pulmonary hypertension in infants and children with congenital heart disease

Bizzarro

Gross

Barbosa³

2014

Cochrane Database of Systematic Reviews

View full text Add to dashboard Cite

show abstract

The Effects of Inhaled Nitric Oxide on Postoperative Pulmonary Hypertension in Infants and Children Undergoing Surgical Repair of Congenital Heart Disease

Cited by 83 publications

References 10 publications

Inhaled Pulmonary Vasodilators: Are There Indications Within the Pediatric ICU?

Inhaled Pulmonary Vasodilators: Are There Indications Within the Pediatric ICU?

Inhaled nitric oxide for the postoperative management of pulmonary hypertension in infants and children with congenital heart disease

Inhaled nitric oxide for the postoperative management of pulmonary hypertension in infants and children with congenital heart disease

Contact Info

Product

Resources

About